Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors (Q38017726)

27 August 2017

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors (English)

1 reference

27 August 2017

1 reference

Larry K Golightly

1

1 reference

27 August 2017

Caitlin C Drayna

series ordinal

2

1 reference

27 August 2017

Michael T McDermott

series ordinal

3

1 reference

27 August 2017

1 August 2012

1 reference

Clinical Pharmacokinetics

27 August 2017

1 reference

27 August 2017

51

1 reference

27 August 2017

501-514

1 reference

27 August 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03261927

27 August 2017

0 references

cites work

Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Impaired regulation of the incretin effect in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

DPP4 inhibitors for diabetes--what next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[([2-[(5-iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]-2-cyano-(S)-pyrrolidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

DPP-4 inhibitors: what may be the clinical differentiators?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

The epidemic of NIDDM in Asian and Pacific Island populations: prevalence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

21 January 2018

Diabetes trends in Japan

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Alogliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjec

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time- and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Effect of sitagliptin on the pharmacokinetics of simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Pharmacokinetics and Pharmacodynamics of Vildagliptin??in??Patients?? with Type??2??Diabetes??Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261927

Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects

21 January 2018

1 reference

12 December 2020

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

1 reference

12 December 2020

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects

1 reference

12 December 2020

Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial

1 reference

12 December 2020

Drug use evaluation of sitagliptin dosing by pharmacist versus nonpharmacist clinicians in an internal medicine department of a private physician-owned multispecialty clinic

1 reference

12 December 2020

The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers

1 reference

12 December 2020

Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin

1 reference

12 December 2020

The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus

1 reference

12 December 2020

AN INTESTINAL HORMONE AFFECTING GLUCOSE DISPOSAL IN MAN

1 reference

12 December 2020

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation

1 reference

12 December 2020

Primary structure of rat liver dipeptidyl peptidase IV deduced from its cDNA and identification of the NH2-terminal signal sequence as the membrane-anchoring domain.

1 reference

12 December 2020

Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole

1 reference

12 December 2020

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.

1 reference

12 December 2020

The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats

1 reference

12 December 2020

Renal impairment with sitagliptin: is there a need for active monitoring of potential renal toxicity?

1 reference

12 December 2020

Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin

1 reference

12 December 2020

Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects

1 reference

12 December 2020

Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers

1 reference

12 December 2020

Intestinal Factors in the Control of Insulin Secretion

1 reference

12 December 2020

Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

12 December 2020

Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects

1 reference

12 December 2020

Selective inhibition of dipeptidyl peptidase 4 by targeting a substrate-specific secondary binding site

1 reference

12 December 2020

Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials

1 reference

12 December 2020

Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction

1 reference

12 December 2020

Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers

1 reference

12 December 2020

The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.

1 reference

12 December 2020

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus

1 reference

12 December 2020

Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers

1 reference

12 December 2020

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION

1 reference

12 December 2020

The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin

1 reference

12 December 2020

Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*)

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03261927

1 reference

Dimensions Publication ID

27 August 2017

0 references

1 reference